New Targeted Therapies Show Promise in Advanced Melanoma
Two new targeted therapies—trametinib and dabrafenib—show promise in the treatment of advanced melanoma, either improving survival or delaying disease progression, according to the results of two...
View ArticleNumber of Cancer Survivors Will Grow to 18 Million by 2022
There will be nearly 18 million cancer survivors in the United States by 2022, according to a report by the American Cancer Society and the National Cancer Institute: Cancer Treatment &...
View ArticleMen, Fertility, and Cancer
Men who confront a cancer diagnosis before beginning or completing their families may have many questions about how cancer treatment will affect their ability to have children in the future. The good...
View ArticleWomen, Fertility and Cancer
Women who confront a cancer diagnosis before beginning or completing their families may have many questions about how cancer treatment will affect their ability to have children in the future. The good...
View ArticleFactors Affecting Quality of Life at the End of Life
For people with advanced cancer, quality of life at the end of life—sometimes referred to as “a good death”—may have less to do with medical treatment and more to do with a therapeutic alliance with...
View ArticleAdjuvant Radiotherapy for the Management of High-Risk Malignant Melanoma
Adjuvant radiotherapy significantly improved regional lymphatic control for high-risk patients after therapeutic lymphadenectomy for metastatic melanoma, according to the results of a study published...
View ArticleCaregivers
What is Caregiving and Who are Caregivers? Caregivers are individuals who provide care to chronically ill or disabled family members or friends. It is estimated that more than one quarter of the adult...
View ArticleAdvanced Directives
Living Wills Every competent adult has, in most cases, the freedom to accept or refuse medical treatment. When you are well, you can talk with your physician and family and make your wishes known....
View ArticleLymphoma Patients and Transplant Recipients at Higher Risk of Melanoma
Individuals with lymphoma or those who have undergone organ transplants are far more likely than the average person to develop—and die from—melanoma, according to the results of a review published in...
View ArticleCombined Targeted Therapy Safe and Effective in Metastatic Melanoma
Treatment with a combination of two targeted agents—dabrafenib, which targets BRAF, and trametinib, which targets MEK—in patients with metastatic melanoma and BRAF V600 mutations was safe and improved...
View ArticleCancer Deaths on the Decline
Overall cancer death rates continue to decline in both men and women and across major ethnic and racial groups, according to the annual Status of Cancer report published in the Journal of the National...
View ArticleAspirin Reduces Risk of Melanoma in Women
Women who regularly take aspirin have a reduced risk of developing melanoma, according to the results of a study published in Cancer.[1] What’s more—the longer they take the aspirin, the lower the...
View ArticleLymphoseek Approved for Detecting Lymph Nodes in Breast Cancer and Melanoma
The U.S. Food and Drug Administration (FDA) has approved Lymphoseek® (technetium Tc 99m tilmanocept) Injection, a radioactive diagnostic imaging agent that helps doctors locate lymph nodes in patients...
View ArticleFollowing Lifestyle Recommendations Reduces Risk of Cancer Death
People who follow the diet and lifestyle recommendations laid out by the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) have a 34 percent reduced risk of dying...
View ArticleIntermittent Zelboraf Treatment in Patients with Melanoma May Prevent...
Tumors resistant to Zelboraf® (vemurafenib) in patients with melanoma showed reduced growth after treatment was stopped. What’s more—animal models have shown that drug resistance was prevented by...
View ArticleImmunotherapy Combination Promising for Metastatic Melanoma
For people with metastatic melanoma, treatment with a combination of Yervoy® (ipilimumab) and Leukine® (sargramostim; GM-CSF) may result in better overall survival than treatment with Yervoy alone....
View ArticleSelumetinib Active Against Melanoma of the Eye
In a Phase II clinical trial, the investigational targeted drug selumetinib resulted in tumor shrinkage in half of patients with advanced melanoma of the eye. These results were presented at the 2013...
View ArticleAnti-PD-1 Drugs Promising for Advanced Melanoma
In Phase I clinical trials, investigational drugs that target a protein known as PD-1 are showing promise for the treatment of advanced melanoma. Results from two of the trials were presented at the...
View ArticleInvestigational Melanoma Drug Shrinks Tumors in Phase III Trial
In a Phase III clinical trial, the investigational drug T-VEC (talimogene laherparepvec) produced durable responses in people with advanced melanoma. These results were presented at the 2013 Annual...
View Article
